<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bleomycin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bleomycin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bleomycin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12410" href="/d/html/12410.html" rel="external">see "Bleomycin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13088" href="/d/html/13088.html" rel="external">see "Bleomycin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708640"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Experienced physician:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">It is recommended that bleomycin be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pulmonary fibrosis is the most severe toxicity associated with bleomycin. The most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis. Its occurrence is higher in elderly patients and in those receiving more than 400 units total dose, but pulmonary toxicity has been observed in young patients and those treated with low doses.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Idiosyncratic reaction: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in approximately 1% of lymphoma patients treated with bleomycin.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F141887"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Antibiotic</li></ul></div>
<div class="block doa drugH1Div" id="F141849"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The risk for pulmonary toxicity increases with age &gt;70 years and cumulative lifetime dose of &gt;400 units.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>International considerations:</b></i>Dosages below expressed as USP units; 1 USP unit = 1 mg (by potency) = 1,000 international units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stefanou.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stefanou.1'])">Ref</a></span>). During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cb13a230-c3e9-4d98-8e1c-329ed6d201bb">Gestational trophoblastic neoplasia, high-risk, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational trophoblastic neoplasia, high-risk, refractory (off-label use): </b>
<i>BEP regimen:</i>
<b> IV:</b> 30 units once weekly, on days 1, 8, and 15 of a 3-week treatment cycle (in combination with etoposide, cisplatin, and WBC growth factor support); continue for at least 2 treatment cycles after a normal hCG level; maximum cumulative bleomycin dose: 270 units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15863169','lexi-content-ref-20626175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15863169','lexi-content-ref-20626175'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma (off-label dosing): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ABVD regimen:</i>
<b> IV:</b> 10 units/m<sup>2</sup> on days 1 and 15 of a 28-day treatment cycle (in combination with doxorubicin, vinblastine, and dacarbazine) for 2 to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15199092','lexi-content-ref-19704068','lexi-content-ref-15315964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15199092','lexi-content-ref-19704068','lexi-content-ref-15315964'])">Ref</a></span>). The number of cycles required and follow-up treatment may be determined by PET scan after 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27332902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27332902'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEACOPP and escalated BEACOPP regimens:</i>
<b>IV:</b> 10 units/m<sup>2</sup> on day 8 of a 21-day treatment cycle (in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) for 4 to 8 cycles; growth factor support is administered with escalated BEACOPP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17018856','lexi-content-ref-12802024','lexi-content-ref-19704068']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17018856','lexi-content-ref-12802024','lexi-content-ref-19704068'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Escalated BEACOPP plus ABVD regimen:</i>
<b>IV:</b> 10 units/m<sup>2</sup> on day 8 of a 21-day treatment cycle (in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and growth factor support) for 2 cycles, followed by 2 cycles of the ABVD regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33539742','lexi-content-ref-22271480']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33539742','lexi-content-ref-22271480'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>EBVP regimen:</i>
<b>IM, IV:</b> 10 units/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with epirubicin, vinblastine, and prednisone) for 6 cycles, then followed by radiation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29229324']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29229324'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Stanford V regimen:</i>
<b>IV:</b> 5 units/m<sup>2</sup> dosed weekly on weeks 2, 4, 6, 8, 10, and 12 (in combination with mechlorethamine, vinblastine, vincristine, doxorubicin, etoposide, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10694546','lexi-content-ref-11821442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10694546','lexi-content-ref-11821442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Test dose for lymphoma patients</i>
<b>
<i>:</i> Note:</b> Test doses may not be predictive of a reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16219896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16219896'])">Ref</a></span>) and/or may produce false-negative results.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM, IV, SUBQ:</b> Due to the possibility of an anaphylactoid reaction, the manufacturer recommends administering bleomycin 2 units or less before the first 2 doses; if no acute reaction occurs, then the regular dosage schedule may be followed. Monitor carefully, particularly following the first 2 doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb6f9e42-e866-4005-b1de-7f8eaab0eec9">Malignant pleural effusion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural effusion:</b>
<b>Intrapleural:</b> 60 units as a single instillation; mix in 50 to 100 mL of NS.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e1bdba6-0de7-42e9-b2e3-f19a8abfb16a">Ovarian germ cell tumors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian germ cell tumors (off-label use):</b>
<i>BEP regimen:</i>
<b>IV:</b> 30 units/dose on days 1, 8, and 15 of a 21-day treatment cycle for 3 cycles (in combination with etoposide and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7512129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7512129'])">Ref</a></span>) <b>or</b> 15 units/m<sup>2</sup> day 1 of a 21-day treatment cycle for 4 cycles (in combination with etoposide and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15226336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15226336'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fffdbf1f-e052-42f2-a151-e1f8a98e129a">Testicular cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Testicular cancer (off-label dosing):</b>
<i>BEP regimen:</i>
<b>IV:</b> 30 units/dose on days 1, 8, and 15 of a 21-day treatment cycle for 3 or 4 cycles (in combination with etoposide and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18202419','lexi-content-ref-9552027','lexi-content-ref-9469360']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18202419','lexi-content-ref-9552027','lexi-content-ref-9469360'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991867"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling </i>(CrCl estimated using the Cockcroft-Gault formula):</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 to 50 mL/minute: Reduce dose to 70% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to 40 mL/minute: Reduce dose to 60% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 to 30 mL/minute: Reduce dose to 55% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 20 mL/minute: Reduce dose to 45% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 5 to 10 mL/minute: Reduce dose to 40% of normal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">The following adjustments have also been recommended:</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl-based dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 46 to 60 mL/minute: Reduce dose to 70% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7859226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7859226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 31 to 45 mL/minute: Reduce dose to 60% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7859226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7859226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute: Consider use of alternative drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7859226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7859226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">eGFR-based dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR 10 to 50 mL/minute/1.73 m<sup>2</sup>: Reduce dose to 75% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">eGFR &lt;10 mL/minute/1.73 m<sup>2</sup>: Reduce dose to 50% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Consider reducing dose to 50% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Reduce dose to 75% of normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989172"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, adjustment for hepatic impairment is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11306728','lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11306728','lexi-content-ref-30942181'])">Ref</a></span>).</p></div>
<div class="block doo drugH1Div" id="F20344378"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>:</i> Fixed doses (dosing which is independent of body weight or BSA), are used in some protocols (eg, testicular cancer); due to toxicity concerns, the same fixed dose should also be considered for patients with a BMI ≥30 kg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F14717181"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary toxicity: Discontinue until determined not to be drug-related.</p>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary diffusion capacity for carbon monoxide (DL<sub>CO</sub>) &lt;30% to 35% of baseline: Discontinue treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary diffusing capacity for carbon monoxide corrected for hemoglobin content [DLCOc] decrease of more than 25% during therapy (compared with baseline): Consider discontinuing bleomycin to avoid further pulmonary toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26903578']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26903578'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F14717786"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. The incidence of pulmonary toxicity is higher in patients &gt;70 years of age.</p></div>
<div class="block dop drugH1Div" id="F141871"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13088" href="/d/html/13088.html" rel="external">see "Bleomycin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> In adults, the risk for pulmonary toxicity increases with cumulative lifetime dose &gt;400 USP units; in pediatric patients, pulmonary function deficits have been seen at cumulative doses ≥60 units/m<sup>2 </sup>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-COG.1','lexi-content-ref-21415131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-COG.1','lexi-content-ref-21415131'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> International considerations: Dosages below are expressed as USP units; 1 USP unit = 1 mg (by potency) = 1,000 international units (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stefanou.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stefanou.1'])">Ref</a></span>). During shortages within the United States, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units. Refer to individual protocols for specific dosage and interval information.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> All doses of bleomycin are associated with a minimal emetic potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>); no routine prophylaxis is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23512831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23512831'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e6b1280d-a88f-4017-a911-d053d510b77f">Germ cell tumors, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Germ cell tumors, malignant:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>PEB regimen</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 0.5 <b>mg</b>/kg on day 1 of a 21-day treatment cycle for 4 cycles in combination with cisplatin and etoposide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15226336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15226336'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: IV: 15 units/m<sup>2</sup> on day 1 of a 21-day treatment cycle for 4 cycles in combination with cisplatin and etoposide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15226336']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15226336'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CEb regimen</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;12 years: IV: 15 units/m<sup>2</sup> on day 3 of a 21-day treatment cycle for 4 to 6 cycles depending on risk stratification in combination with carboplatin and etoposide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34665989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34665989'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3e240540-8f7b-4f63-a0fb-80c94e299f1a">Germ cell tumors, nonseminomatous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Germ cell tumors, nonseminomatous: </b>Limited data available: <b>Note:</b> Dosing based on trials conducted outside of the United States; dosing presented in units based on milligram potency of product.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VBP regimen</i>: Intermediate risk: Children and Adolescents: IV: 15 units/m<sup>2</sup> on days 1 and 2 for 3 to 5 cycles in combination with cisplatin and vinblastine; cycle duration not reported; based on pharmacology of protocol and likely nadir, a 21-day cycle seems likely; however, refer to protocol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36451268','lexi-content-ref-34146403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36451268','lexi-content-ref-34146403'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although described in the manufacturer's labeling, test doses may not be predictive of a reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16219896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16219896'])">Ref</a></span>) and/or may produce false-negative results; some protocols no longer require; refer to institution/protocol-specific guidelines.</p>
<p style="text-indent:-2em;margin-left:4em;">High risk:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>ABVE-PC</i>: Children and Adolescents: IV or SUBQ: 5 units/m<sup>2</sup> on day 1 and 10 units/m<sup>2</sup> on day 8 of a 21-day cycle for 2 to 4 cycles in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322844','lexi-content-ref-35187850','lexi-content-ref-25542311','lexi-content-ref-25311218','lexi-content-ref-31180135','lexi-content-ref-19584400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322844','lexi-content-ref-35187850','lexi-content-ref-25542311','lexi-content-ref-25311218','lexi-content-ref-31180135','lexi-content-ref-19584400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>ABVD</i>: Children and Adolescents: IV: 10 units/m<sup>2</sup> on days 1 and 15 of a 28-day treatment cycle for 2 to 6 cycles in combination with doxorubicin, vinblastine, and dacarbazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35187850','lexi-content-ref-9508171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35187850','lexi-content-ref-9508171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>BEACOPP</i>: Children and Adolescents: IV: 10 units/m<sup>2</sup> on day 7 of a 21-day treatment cycle for 2 to 4 cycles in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12078889']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12078889'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Stanford V</i>: Adolescents ≥16 years: IV: 5 units/m<sup>2</sup> in weeks 2, 4, 6, 8, 10, and 12 of a 12-week treatment cycle for 1 cycle in combination with mechlorethamine, vinblastine, vincristine, doxorubicin, etoposide, and prednisone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23182987','lexi-content-ref-10694546','lexi-content-ref-11821442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23182987','lexi-content-ref-10694546','lexi-content-ref-11821442'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermediate risk:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>ABVE-PC regimen</i>: Children and Adolescents: IV or SUBQ: 5 units/m<sup>2</sup> on day 1 and 10 units/m<sup>2</sup> on day 8 of a 21-day cycle for 2 to 4 cycles in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35187850','lexi-content-ref-30277639','lexi-content-ref-19584400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35187850','lexi-content-ref-30277639','lexi-content-ref-19584400'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>COPP/ABV regimen</i>: <b>Note:</b> Dosing based on trials conducted outside of the United States; dosing presented in units based on milligram potency of product. Children and Adolescents: IV: 10 units/m<sup>2</sup> on day 8 of a 28-day treatment cycle for 4 to 6 cycles in combination with cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, and vinblastine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27960645','lexi-content-ref-27162323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27960645','lexi-content-ref-27162323'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary toxicity: Discontinue until determined not to be drug related.</p>
<p style="text-indent:-2em;margin-left:6em;">Pulmonary diffusion capacity for carbon monoxide (DL<sub>CO</sub>) &lt;30% to 35% of baseline: Discontinue treatment.</p></div>
<div class="block dorp drugH1Div" id="F51258219"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51073593"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); however, adjustment for hepatic impairment is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11306728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11306728'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F141815"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Dermatologic: Atrophic striae (~50%), erythema of skin (~50%), hyperpigmentation (~50%), skin rash (~50%), skin tenderness (~50%), vesicular eruption (~50%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary toxicity (10%; including dyspnea, pneumonitis, pulmonary fibrosis, rales)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Local: Local pain (intrapleural administration)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Cardiotoxicity (including acute myocardial infarction, coronary artery disease, ischemic heart disease, pericarditis) (Didagelos 2013), chest pain (during infusion), hypotension, phlebitis, Raynaud disease (McGrath 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (Siegel 1990), dermatological reaction (including exfoliation of the skin [particularly on palmar and plantar surfaces], flagellate rash, hyperkeratosis, nailbed changes) (Agrawal 2017, Chen 2007, Lee 2014), pruritus (Lee 2014), skin sclerosis (Kim 1996), Stevens-Johnson syndrome (Giaccone 1986)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, stomatitis (Siegel 1990), vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic uremic syndrome (Salhi 2020), thrombotic microangiopathy (Salhi 2020), tumor pain</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Khansur 1984)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, malaise</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrotoxicity</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, hyperpyrexia (Jhatial 2022)</p></div>
<div class="block coi drugH1Div" id="F141830"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity or idiosyncratic reaction to bleomycin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F141812"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: May cause hepatic toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Idiosyncratic reaction: A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing (similar to anaphylaxis) has been reported in 1% of lymphoma patients treated with bleomycin. Since these reactions usually occur after the first or second dose, careful monitoring is essential after these doses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Occurrence of pulmonary fibrosis (commonly presenting as pneumonitis; occasionally progressing to pulmonary fibrosis) is the most severe toxicity. Risk is higher in elderly patients or patients receiving &gt;400 units total lifetime dose; other possible risk factors include smoking and patients with prior radiation therapy or receiving concurrent oxygen (especially high inspired oxygen doses). A review of patients receiving bleomycin for the treatment of germ cell tumors suggests risk for pulmonary toxicity is increased in patients &gt;40 years of age, with glomerular filtration rate &lt;80 mL/minute, advanced disease, and cumulative bleomycin doses &gt;300 units (O’Sullivan 2003). Pulmonary toxicity may include bronchiolitis obliterans and organizing pneumonia (BOOP), eosinophilic hypersensitivity, and interstitial pneumonitis, progressing to pulmonary fibrosis (Sleijfer 2001); pulmonary toxicity may be due to a lack of the enzyme which inactivates bleomycin (bleomycin hydrolase) in the lungs (Morgan 2011; Sleijfer 2001), If pulmonary changes occur, withhold treatment and investigate if drug-related. In a study of patients with testicular cancer receiving bleomycin as part of the BEP regimen, pulmonary function testing (including forced vital capacity [FVC], forced expiratory volume in 1 second [FEV<sub>1</sub>], and diffusing capacity of the lungs for carbon monoxide [DLCO]) was performed prior to treatment, before each chemotherapy cycle, and then repeated at 1 year, 3 years, and 5 years during follow up; if the carbon monoxide diffusing capacity corrected for hemoglobin content [DLCOc] decreased more than 25% during therapy (compared with baseline), bleomycin was discontinued to avoid further pulmonary toxicity (Lauritsen 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: May cause renal toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hodgkin lymphoma: Positron emission tomography/computed tomography (PET/CT) may have a role in determining early response to therapy in patients with Hodgkin lymphoma; a negative interim PET/CT result after 2 cycles may indicate that bleomycin can be safely omitted from the ABVD treatment regimen (Johnson 2016). Longer follow-up is necessary to determine the effect of bleomycin omission on long-term morbidity and mortality in these patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: In children, a younger age at treatment, cumulative dose ≥400 units/m<sup>2</sup> (combined with chest irradiation), and renal impairment are associated with a higher incidence of pulmonary toxicity (Huang 2011). Pulmonary function deficits at doses as low as 60 to 120 units/m<sup>2</sup> in children on formal pulmonary function testing have been reported (COG 2018; Huang 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• International issues: Some products available internationally may have vial strength and dosing expressed as international units or milligrams (instead of units or USP units). During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units. One USP unit of bleomycin = 1 mg (by potency) = 1,000 international units (Stefanou 2001). Refer to prescribing information for specific dosing information.</p>
<p style="text-indent:-2em;margin-left:4em;">• O<sub>2</sub> during surgery: Use caution when administering O<sub>2</sub> during surgery to patients who have received bleomycin; the risk of bleomycin-related pulmonary toxicity is increased.</p></div>
<div class="block dosfc drugH1Div" id="F47062016"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units (1,000 international units = 1 USP unit).</p></div>
<div class="block foc drugH1Div" id="F141823"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 units (1 ea); 30 units (1 ea)</p></div>
<div class="block geq drugH1Div" id="F141808"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323022"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Bleomycin Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 unit (per each): $36.82 - $68.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 unit (per each): $80.03 - $127.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866096"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 15 units (1 ea)</p></div>
<div class="block adm drugH1Div" id="F141827"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> IV doses should be administered slowly over 10 minutes (according to the manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM or SUBQ:</b> May cause pain at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrapleural:</b> 60 units in 50 to 100 mL NS; use of topical anesthetics or opioid analgesia is usually not necessary</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for hypersensitivity, particularly following the first 2 doses in patients with lymphoma.</p></div>
<div class="block admp drugH1Div" id="F52612315"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IM, SUBQ: Administer at a concentration of 3 to 15 units/mL; may cause pain at injection site.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer IV slowly over at least 10 minutes; may be further diluted for administration by continuous IV infusion; slower administration may produce less severe pulmonary toxicity.</p></div>
<div class="block hazard drugH1Div" id="F49130900"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F141826"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Head and neck cancers:</b> Treatment of squamous cell carcinoma of the head and neck.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma:</b> Treatment of Hodgkin lymphoma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural effusion:</b> Sclerosing agent for malignant pleural effusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Testicular cancer:</b> Treatment of testicular cancer.</p></div>
<div class="block off-label drugH1Div" id="F25721944"><span class="drugH1">Use: Off-Label: Adult</span><p>Germ cell tumors, malignant; Gestational trophoblastic neoplasia, high-risk, refractory</p></div>
<div class="block mst drugH1Div" id="F141898"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Bleomycin may be confused with Cleocin, clindamycin.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Some products available internationally may have vial strength and dosing expressed as international units or milligrams (instead of units or USP units). Refer to prescribing information for specific strength and dosing information.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units (1,000 international units = 1 USP unit).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298875"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F141817"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Brentuximab Vedotin: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemcitabine: May enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Granulocyte Colony-Stimulating Factors: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. Management: Avoid use of granulocyte colony-stimulating factors 24 hours before (14 days for pegfilgrastim) and 24 hours after the last dose of bleomycin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxygen: May enhance the adverse/toxic effect of Bleomycin. Specifically, bleomycin pulmonary toxicity may be enhanced. Management: Attempt to keep oxygen at a concentration equal to that of room air (eg, 25%), during surgery and the post-operative period for patients receiving bleomycin. Monitor patients carefully for pulmonary toxicity, especially those receiving fluid replacement.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Bleomycin may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095588"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">According to the manufacturer, patients who could become pregnant should avoid becoming pregnant during bleomycin treatment.</p></div>
<div class="block pri drugH1Div" id="F3013953"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse effects were observed in animal reproduction studies. The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]). When multiagent therapy is needed to treat Hodgkin lymphoma during pregnancy, bleomycin (as a component of the ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] regimen) may be used, starting with the second trimester (ESMO [Peccatori 2013]; Follows 2014).</p></div>
<div class="block brc drugH1Div" id="F3013955"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if bleomycin is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F141821"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Pulmonary function tests, including total lung volume, forced vital capacity, diffusion capacity for carbon monoxide; vital capacity, total lung capacity and pulmonary capillary blood volume may be better indicators of changes induced by bleomycin (Sleifjer 2001); forced vital capacity [FVC], forced expiratory volume in 1 second [FEV<sub>1</sub>], and diffusing capacity of the lungs for carbon monoxide [DLCO]) were performed prior to treatment, before each chemotherapy cycle, and then repeated at 1 year, 3 years, and 5 years during follow up for testicular cancer patients receiving bleomycin (Lauritsen 2016); chest x-ray, renal function, liver function. Monitor for signs/symptoms of hypersensitivity; temperature initially; check body weight at regular intervals.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F141811"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Bleomycin inhibits synthesis of DNA; binds to DNA leading to single- and double-strand breaks; also inhibits (to a lesser degree) RNA and protein synthesis.</p></div>
<div class="block phk drugH1Div" id="F141829"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: IM, SubQ, and intrapleural administration: 100%, 70%, and 45%, respectively, of IV serum concentrations</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: IV: 17.5 L/m<sup>2</sup></p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 1% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Enzymatic inactivation by bleomycin hydrolase, a cytosolic cysteine proteinase enzyme; bleomycin hydrolase is widely distributed in normal tissues (except for the skin and lungs)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: IV: 2 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: IM, SubQ, Intrapleural: 30 to 60 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~65% [IV], 40% [Intrapleural])</p></div>
<div class="block phksp drugH1Div" id="F51154035"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The half-life increases exponentially as CrCl decreases.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Children &lt;3 years of age have a higher total body clearance than adults, 71 mL/minute/m<sup>2</sup> vs 51 mL/minute/m<sup>2</sup>, respectively, following IV bolus administration. Children ≥8 years of age have comparable clearance to adults. In children with normal renal function, plasma concentrations of bleomycin decline biexponentially as in adults. The volume of distribution and terminal half-life of bleomycin in children appear comparable to those in adults (Yee 1983; manufacturer's labeling).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F141832"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bileco | Bleocris | Bleomicina asofarma | Bleomicina dosa | Blocamicina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bleomycin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Blenamax | Blenoxane | Bleo | Bleomycin cipla | Bleomycin sulphate</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Bleomin | Bleomycine | Bleomycine accord</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleomycin | Bleomycin medac | Bleomycine teva</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Blenoxane | Bonar | Cinaleo | Tecnomicina | Tevableo</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Bleomycin teva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bleomicina | Blexit</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleomycin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Blenamax | Bleolem | Bleomicina | Bleoseven 15 | Blexicip | Blomindex | Oncobleocin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bleomedac | Bleomycin teva</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Bleo cell | Bleomedac | Bleomicina | Bleomycin | Bleomycin teva | Bleomycinum</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bleocip</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Bleocris | Bleomicina | Oncobleocin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bleo cell | Bleocel | Bleolem | Bleomycin medac</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bleocin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Bleomicina | Bleomicina accord</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleomycin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bleomycin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bleomycine Bellon | Bleomycine teva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bleo kyowa | Bleomycin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bleocin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Bleocin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Bleocin s</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bleo cell | Bleomycin teva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bleocin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Bleocel | Bleochem | Bleocip | Bleomycin sulphate | Bleonco | Bleotex | Lyoble | Tumocin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bleomicina | Bleomicina crinos | Bleomicina Teva | Bleoprim</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bleo</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Bleochem | Bleocip</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bloicin s | Union bleomycin sulfate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lyoble</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleolem | Bleomycetin | Bleomycin medac | Bleomycin Mylan | Bleomycin teva</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bleomycine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bleomycetin | Bleomycin | Bleomycin medac | Bleomycin teva</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Bleomycine | Blucin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bleolem | Bleomax | Bleomicina | Blomindex</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Blenamax | Dbl bleomycin sulfate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bleomedac | Bleomycine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bleomicina | Bleomycin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bileco | Bleocin | Bleomicina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bemocin | Tumocin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleomycin | Bleotex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Blemisin | Bleocel | Bleocin | Bleomedac | Bleomycin | Bleomycin Hexal | Bleomycin teva</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Blenoxane | Bleo | Bleomycin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleomedac | Bleomicina ApS | Bleomicina Teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Bleocris | Bleomicina fapasa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleomicina accord | Bleomycin medac | Bleomycine Bellon</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Blenamax | Bleocin | Bleomycetin | Bleomycetin hydrochloride | Bleomycin ronc | Maltin | Vero bleomycin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bemocin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bleomycin baxter</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Blenamax | Bleomycin sulphate | Bleomycinum</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleomedac</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Blenamax | Bleochem | Bleocin | Bleolem</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Bleomycine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Blemisin | Bleolem</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleomycin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bleocin | Bleocin c | Bleolem | Bleomycin | Lyoble 15</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Bleosol</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Bileco | Bleocina | Bleocris | Bleomicina</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Blenamax | Blenoxane | Bleocel | Bleolem</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Bleocip | Bleomycin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Bemocin | Bleocip | Blesol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29333029">
<a name="29333029"></a>Agrawal C, Talwar V, Saini R, Babu P. Flagellate rash: an unusual complication of bleomycin therapy - a case report with brief review of literature. <i>Indian J Med Paediatr Oncol</i>. 2017;38(4):548-551. doi:10.4103/ijmpo.ijmpo_147_16<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/29333029/pubmed" id="29333029" target="_blank">29333029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007:97.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15939315">
<a name="15939315"></a>Azambuja E, Fleck JF, Batista RG, et al. Bleomycin Lung Toxicity: Who are the Patients With Increased Risk? <i>Pulm Pharmacol Ther</i>. 2005;18(5):363-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/15939315/pubmed" id="15939315" target="_blank">15939315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BMS.1">
<a name="BMS.1"></a>Blenoxane (bleomycin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; April 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Bleomycin [prescribing information]. Lake Forest, IL: Hospira; May 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Bleomycin [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc; February 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fresenius.1">
<a name="Fresenius.1"></a>Bleomycin [product monograph]. Richmond Hill, ON: Fresenius Kabi Canada Ltd; February 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15199092">
<a name="15199092"></a>Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. <i>J Clin Oncol</i>. 2004;22(14):2835-2841. doi:10.1200/JCO.2004.12.170<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/15199092/pubmed" id="15199092" target="_blank">15199092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33539742">
<a name="33539742"></a>Borchmann P, Plütschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.<i> Lancet Oncol.</i> 2021;22(2):223-234. doi:10.1016/S1470-2045(20)30601-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/33539742/pubmed" id="33539742" target="_blank">33539742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17577017">
<a name="17577017"></a>Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects. <i>J Clin Oncol</i>. 2007;25(25):3991-4008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/17577017/pubmed" id="17577017" target="_blank">17577017</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322844">
<a name="36322844"></a>Castellino SM, Pei Q, Parsons SK, et al. Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin's lymphoma. <i>N Engl J Med</i>. 2022;387(18):1649-1660. doi:10.1056/NEJMoa2206660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/36322844/pubmed" id="36322844" target="_blank">36322844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17327612">
<a name="17327612"></a>Chen YB, Rahemtullah A, Breeden E, Hochberg EP. Bleomycin-induced flagellate erythema. <i>J Clin Oncol</i>. 2007;25(7):898-900. doi:10.1200/JCO.2006.09.7691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/17327612/pubmed" id="17327612" target="_blank">17327612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-COG.1">
<a name="COG.1"></a>Children's Oncology Group (COG). Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. Version 5.0. Published October 2018. Accessed September 28, 2023. http://www.survivorshipguidelines.org/pdf/2018/COG_LTFU_Guidelines_v5.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18202419">
<a name="18202419"></a>Culine S, Kramar A, Théodore C, et al. Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. <i>J Clin Oncol</i>. 2008;26(3):421-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/18202419/pubmed" id="18202419" target="_blank">18202419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15226336">
<a name="15226336"></a>Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study -- Pediatric Oncology Group 9049 and Children's Cancer Group 8882. <i>J Clin Oncol</i>. 2004;22(13):2691-2700.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/15226336/pubmed" id="15226336" target="_blank">15226336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17018856">
<a name="17018856"></a>Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-Adapted BEACOPP Regimen Can Reduce the Cumulative Dose of Chemotherapy for Standard and High-Risk Hodgkin Lymphoma With No Impairment of Outcome. <i>Blood</i>. 2007;109(3):905-909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/17018856/pubmed" id="17018856" target="_blank">17018856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35187850">
<a name="35187850"></a>de Armas S, Huertas-Ayala C, Chan RY, et al. Survival of pediatric Hodgkin lymphoma patients treated with doxorubicin, bleomycin, vincristine, etoposide, prednisone, and cyclophosphamide (ABVE-PC) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) at a single institution. <i>Pediatr Blood Cancer</i>. 2022;69(5):e29601. doi:10.1002/pbc.29601<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/35187850/pubmed" id="35187850" target="_blank">35187850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22271474">
<a name="22271474"></a>de Wit R, Skoneczna I, Daugaard G, et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. <i>J Clin Oncol.</i> 2012;30(8):792-799.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/22271474/pubmed" id="22271474" target="_blank">22271474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25542311">
<a name="25542311"></a>Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. <i>Int J Radiat Oncol Biol Phys</i>. 2015;92(1):60-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/25542311/pubmed" id="25542311" target="_blank">25542311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24376332">
<a name="24376332"></a>Didagelos M, Boutis A, Diamantopoulos N, Sotiriadou M, Fotiou C. Bleomycin cardiotoxicity during chemotherapy for an ovarian germ cell tumor. <i>Hippokratia</i>. 2013;17(2):187-188.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/24376332/pubmed" id="24376332" target="_blank">24376332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12802024">
<a name="12802024"></a>Diehl V, Franklin J, Pfreundschuh M, et al. Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease. <i>N Engl J Med</i>. 2003;348(24):2386-2395.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/12802024/pubmed" id="12802024" target="_blank">12802024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patient. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384141">
<a name="33384141"></a>Eiriksson L, Dean E, Sebastianelli A, et al. Guideline no. 408: management of gestational trophoblastic diseases. <i>J Obstet Gynaecol Can</i>. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/33384141/pubmed" id="33384141" target="_blank">33384141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19704068">
<a name="19704068"></a>Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. <i>J Clin Oncol.</i> 2009;27(27):4548-4554. doi:10.1200/JCO.2008.19.8820<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/19704068/pubmed" id="19704068" target="_blank">19704068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17606976">
<a name="17606976"></a>Engert A, Franklin J, Eich HT, et al. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial. <i>J Clin Oncol</i>. 2007;25(23):3495-3502.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/17606976/pubmed" id="17606976" target="_blank">17606976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20818855">
<a name="20818855"></a>Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. <i>N Engl J Med</i>. 2010;363(7):640-652. doi:10.1056/NEJMoa1000067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/20818855/pubmed" id="20818855" target="_blank">20818855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36451268">
<a name="36451268"></a>Faure-Conter C, Orbach D, Sudour-Bonnange H, et al. Extracranial germ cell tumours in children and adolescents: results from the French TGM13 protocol. <i>Pediatr Blood Cancer</i>. 2023;70(3):e30117. doi:10.1002/pbc.30117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/36451268/pubmed" id="36451268" target="_blank">36451268</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of Cancer Therapy. <i>J Clin Oncol</i>. 2005;23(30):7685-7696.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24712411">
<a name="24712411"></a>Follows GA, Ardeshna KM, Barrington SF, et al. Guidelines for the first line management of classical Hodgkin lymphoma.<i> Br J Haematol</i>. 2014;166(1):34-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/24712411/pubmed" id="24712411" target="_blank">24712411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25311218">
<a name="25311218"></a>Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. <i>J Clin Oncol</i>. 2014;32(32):3651-3658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/25311218/pubmed" id="25311218" target="_blank">25311218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2426851">
<a name="2426851"></a>Giaccone G, Risio M, Bonardi G, Calciati A. Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin: a case report. <i>Tumori</i>. 1986;72(3):331-333. doi:10.1177/030089168607200316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/2426851/pubmed" id="2426851" target="_blank">2426851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23182987">
<a name="23182987"></a>Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>J Clin Oncol</i>. 2013;31(6):684-691.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/23182987/pubmed" id="23182987" target="_blank">23182987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10694546">
<a name="10694546"></a>Horning SJ, Williams J, Bartlett NL, et al. Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492. <i>J Clin Oncol</i>. 2000;18(5):972-980.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/10694546/pubmed" id="10694546" target="_blank">10694546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11821442">
<a name="11821442"></a>Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. <i>J Clin Oncol.</i> 2002;20(3):630-637.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/11821442/pubmed" id="11821442" target="_blank">11821442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19738111">
<a name="19738111"></a>Hoskin PJ, Lowry L, Horwich A, et al. Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. <i>J Clin Oncol</i>. 2009;27(32):5390-5396.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/19738111/pubmed" id="19738111" target="_blank">19738111</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21415131">
<a name="21415131"></a>Huang TT, Hudson MM, Stokes DC, et al. Pulmonary outcomes in survivors of childhood cancer: a systematic review. <i>Chest</i>. 2011;140(4):881-901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/21415131/pubmed" id="21415131" target="_blank">21415131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9508171">
<a name="9508171"></a>Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group phase III trial. <i>J Clin Oncol</i>. 1998;16(3):897-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/9508171/pubmed" id="9508171" target="_blank">9508171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21142531">
<a name="21142531"></a>Ibrahimi OA, Anderson RR. Images in Clinical Medicine. Bleomycin-Induced Flagellate Hyperpigmentation. <i>N Engl J Med</i>. 2010;363(24):e36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/21142531/pubmed" id="21142531" target="_blank">21142531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34665989">
<a name="34665989"></a>Jain R, Menon P, Bansal D, et al. Outcome of pediatric germ cell tumor with comparison of carboplatin and cisplatin based regimens: a 10-year analysis. <i>Pediatr Hematol Oncol</i>. 2022;39(3):267-277. doi:10.1080/08880018.2021.1980164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/34665989/pubmed" id="34665989" target="_blank">34665989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36340558">
<a name="36340558"></a>Jhatial MA, Bin Naeem S, Abbas M, et al. Bleomycin-induced fulminant hyperpyrexia: a report of two cases and review of literature. <i>Cureus</i>. 2022;14(9):e29785. doi:10.7759/cureus.29785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/36340558/pubmed" id="36340558" target="_blank">36340558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27332902">
<a name="27332902"></a>Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. <i>N Engl J Med</i>. 2016;374(25):2419-2429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/27332902/pubmed" id="27332902" target="_blank">27332902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16314615">
<a name="16314615"></a>Johnson PW, Radford JA, Cullen MH, et al. Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). <i>J Clin Oncol</i>. 2005;23(36):9208-9218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/16314615/pubmed" id="16314615" target="_blank">16314615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180135">
<a name="31180135"></a>Kelly KM, Cole PD, Pei Q, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. <i>Br J Haematol</i>. 2019;187(1):39-48. doi:10.1111/bjh.16014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/31180135/pubmed" id="31180135" target="_blank">31180135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12078889">
<a name="12078889"></a>Kelly KM, Hutchinson RJ, Sposto R, et al; Children's Oncology Group. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. <i>Ann Oncol</i>. 2002;13(suppl 1):107-111. doi:10.1093/annonc/13.s1.107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/12078889/pubmed" id="12078889" target="_blank">12078889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6208860">
<a name="6208860"></a>Khansur T, Little D, Tavassoli M. Fulminant and fatal angioedema caused by bleomycin treatment. <i>Arch Intern Med</i>. 1984;144(11):2267. doi:10.1001/archinte.144.11.2267<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/6208860/pubmed" id="6208860" target="_blank">6208860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8934404">
<a name="8934404"></a>Kim KH, Yoon TJ, Oh CW, Ko GH, Kim TH. A case of bleomycin-induced scleroderma. <i>J Korean Med Sci</i>. 1996;11(5):454-456. doi:10.3346/jkms.1996.11.5.454<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/8934404/pubmed" id="8934404" target="_blank">8934404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11306728">
<a name="11306728"></a>King PD, Perry MC. Hepatotoxicity of Chemotherapy. <i>Oncologist</i>. 2001;6(2):162-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/11306728/pubmed" id="11306728" target="_blank">11306728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE, Dorr RT. Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function. <i>Cancer Treat Rev</i>. 1995;21(1):33-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16219896">
<a name="16219896"></a>Lam MS. The Need for Routine Bleomycin Test Dosing in the 21st Century. <i>Ann Pharmacother</i>. 2005;39(11):1897-1902.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/16219896/pubmed" id="16219896" target="_blank">16219896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26903578">
<a name="26903578"></a>Lauritsen J, Kier MG, Bandak M, et al. Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin. <i>J Clin Oncol</i>. 2016;34(13):1492-1499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/26903578/pubmed" id="26903578" target="_blank">26903578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25009666">
<a name="25009666"></a>Lee HY, Lim KH, Ryu Y, Song SY. Bleomycin-induced flagellate erythema: a case report and review of the literature. <i>Oncol Lett</i>. 2014;8(2):933-935. doi:10.3892/ol.2014.2179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/25009666/pubmed" id="25009666" target="_blank">25009666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15863169">
<a name="15863169"></a>Lurain JR, Nejad B. Secondary chemotherapy for high-risk gestational trophoblastic neoplasia. <i>Gynecol Oncol.</i> 2005;97(2):618-623. doi:10.1016/j.ygyno.2005.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/15863169/pubmed" id="15863169" target="_blank">15863169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22696816">
<a name="22696816"></a>Lurain JR, Schink JC. Importance of salvage therapy in the management of high-risk gestational trophoblastic neoplasia. <i>J Reprod Med</i>. 2012;57(5-6):219-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/22696816/pubmed" id="22696816" target="_blank">22696816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20626175">
<a name="20626175"></a>Lurain JR, Singh DK, Schink JC. Management of metastatic high-risk gestational trophoblastic neoplasia: FIGO stages II-IV: risk factor score &gt; or = 7. <i>J Reprod Med</i>. 2010;55(5-6):199-207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/20626175/pubmed" id="20626175" target="_blank">20626175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30277639">
<a name="30277639"></a>Marks LJ, Pei Q, Bush R, et al. Outcomes in intermediate-risk pediatric lymphocyte-predominant Hodgkin lymphoma: a report from the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2018;65(12):e27375. doi:10.1002/pbc.27375<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/30277639/pubmed" id="30277639" target="_blank">30277639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23270004">
<a name="23270004"></a>McGrath SE, Webb A, Walker-Bone K. Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion. <i>J Clin Oncol</i>. 2013;31(4):e51-e52. doi:10.1200/JCO.2012.43.2872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/23270004/pubmed" id="23270004" target="_blank">23270004</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9552027">
<a name="9552027"></a>Nichols CR, Catalano PJ, Crawford ED, et al. Randomized Comparison of Cisplatin and Etoposide and Either Bleomycin or Ifosfamide in Treatment of Advanced Disseminated Germ Cell Tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. <i>J Clin Oncol</i>. 1998;16(4):1287-1293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/9552027/pubmed" id="9552027" target="_blank">9552027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12488299">
<a name="12488299"></a>O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. <i>Ann Oncol</i>. 2003;14(1):91-96. doi:10.1093/annonc/mdg020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/12488299/pubmed" id="12488299" target="_blank">12488299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34146403">
<a name="34146403"></a>Pavone R, Pacquement H, Pasquet M, et al. Childhood ovarian nonseminomatous germ cell tumors: a highly curable disease with few long-term treatment-related toxicities-results of the French TGM95 study. <i>Int J Cancer</i>. 2021;149(9):1705-1712. doi:10.1002/ijc.33710<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/34146403/pubmed" id="34146403" target="_blank">34146403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perry.2012">
<a name="Perry.2012"></a>Perry MC. Chemotherapeutic agents: bleomycin. <i>The Chemotherapy Source Boo</i>k. 5th ed. Philadelphia, PA: 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33841872">
<a name="33841872"></a>Salhi S, Ribes D, Faguer S. Complement C5 inhibition reverses bleomycin-induced thrombotic microangiopathy. <i>Clin Kidney J</i>. 2020;14(4):1275-1276. doi:10.1093/ckj/sfaa101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/33841872/pubmed" id="33841872" target="_blank">33841872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9469360">
<a name="9469360"></a>Saxman SB, Finch D, Gonin R, et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. <i>J Clin Oncol. </i>1998;16(2):702-706. doi:10.1200/JCO.1998.16.2.702<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/9469360/pubmed" id="9469360" target="_blank">9469360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19584400">
<a name="19584400"></a>Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/19584400/pubmed" id="19584400" target="_blank">19584400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27960645">
<a name="27960645"></a>Seror E, Donadieu J, Pacquement H, et al. Combined therapy in children and adolescents with classical Hodgkin's lymphoma: a report from the SFCE on MDH-03 national guidelines. <i>Pediatr Hematol Oncol</i>. 2016;33(7-8):423-437. doi:10.1080/08880018.2016.1247393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/27960645/pubmed" id="27960645" target="_blank">27960645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1695874">
<a name="1695874"></a>Siegel RD, Schiffman FJ. Systemic toxicity following intracavitary administration of bleomycin. <i>Chest</i>. 1990;98(2):507. doi:10.1378/chest.98.2.507<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/1695874/pubmed" id="1695874" target="_blank">1695874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11502668">
<a name="11502668"></a>Sleijfer S. Bleomycin-Induced Pneumonitis. <i>Chest</i>. 2001;120(2):617-624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/11502668/pubmed" id="11502668" target="_blank">11502668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stefanou.1">
<a name="Stefanou.1"></a>Stefanou A, MacCallum P, and Siderov J. Errors due to bleomycin nomenclature. <i>BMJ.</i> 2001;322(7299):548.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15315964">
<a name="15315964"></a>Straus DJ, Portlock CS, Qin J, et al. Results of a Prospective Randomized Clinical Trial of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Followed by Radiation Therapy (RT) Versus ABVD Alone for stages I, II, and IIIA Nonbulky Hodgkin Disease. <i>Blood</i>. 2004;104(12):3483-3489.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/15315964/pubmed" id="15315964" target="_blank">15315964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29229324">
<a name="29229324"></a>Thomas J, Fermé C, Noordijk EM, et al. Comparison of 36 Gy, 20 Gy, or no radiation therapy after 6 cycles of EBVP chemotherapy and complete remission in early-stage Hodgkin lymphoma without risk factors: results of the EORT-GELA H9-F Intergroup randomized trial. <i>Int J Radiat Oncol Biol Phys.</i> 2018;100(5):1133-1145. doi:10.1016/j.ijrobp.2017.10.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/29229324/pubmed" id="29229324" target="_blank">29229324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19875337">
<a name="19875337"></a>Tobias JS, Monson K, Gupta N, et al. Chemoradiotherapy for Locally Advanced Head and Neck Cancer: 10-year Follow-Up of the UK Head and Neck (UKHAN1) Trial. <i>Lancet Oncol</i>. 2010;11(1):66-74.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/19875337/pubmed" id="19875337" target="_blank">19875337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22271480">
<a name="22271480"></a>von Tresckow B, Plütschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. <i>J Clin Oncol.</i> 2012;30(9):907-913. doi:10.1200/JCO.2011.38.5807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/22271480/pubmed" id="22271480" target="_blank">22271480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19863338">
<a name="19863338"></a>Wiernik PH, Hong F, Glick JH, et al. Radiation Therapy Compared With Chemotherapy for Consolidation of Chemotherapy-Induced Remission of Advanced Hodgkin Lymphoma: A Study by the Eastern Co-Operative Oncology Group (E1476) With &gt;20 Years Follow-Up. <i>Leuk Lymphoma</i>. 2009;50(10):1632-1641.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/19863338/pubmed" id="19863338" target="_blank">19863338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7512129">
<a name="7512129"></a>Williams S, Blessing JA, Liao SY, et al. Adjuvant Therapy of Ovarian Germ Cell Tumors With Cisplatin, Etoposide, and Bleomycin: A Trial of the Gynecologic Oncology Group. <i>J Clin Oncol</i>. 1994;12(4):701-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/7512129/pubmed" id="7512129" target="_blank">7512129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6188571">
<a name="6188571"></a>Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE. Bleomycin disposition in children with cancer. <i>Clin Pharmacol Ther</i>. 1983;33(5):668-673. doi:10.1038/clpt.1983.91<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/6188571/pubmed" id="6188571" target="_blank">6188571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27162323">
<a name="27162323"></a>Zhen Z, Guo X, Zhu J, et al. Effect of chemotherapy alone with adult chemotherapy regimens on prognosis of children and adolescents with Hodgkin's disease. <i>Jpn J Clin Oncol</i>. 2016;46(7):667-673. doi:10.1093/jjco/hyw051<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/27162323/pubmed" id="27162323" target="_blank">27162323</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9160 Version 254.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
